Published in Genome Biol on November 17, 2016
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc (2009) 137.99
TopHat: discovering splice junctions with RNA-Seq. Bioinformatics (2009) 81.13
Differential expression analysis for sequence count data. Genome Biol (2010) 64.56
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med (1995) 26.60
STAR: ultrafast universal RNA-seq aligner. Bioinformatics (2012) 25.21
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
HTSeq--a Python framework to work with high-throughput sequencing data. Bioinformatics (2014) 23.22
Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics (2006) 22.61
Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature (2013) 20.16
Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal (2013) 19.54
Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med (2014) 16.83
Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature (2013) 13.60
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature (2014) 12.00
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (2015) 11.89
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources. Genome Biol (2009) 11.17
Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol (2012) 10.87
PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature (2014) 10.39
ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics (2009) 8.60
The three Es of cancer immunoediting. Annu Rev Immunol (2004) 8.20
Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell (2006) 8.09
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature (2012) 7.76
Random forest: a classification and regression tool for compound classification and QSAR modeling. J Chem Inf Comput Sci (2003) 5.93
Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet (2014) 5.74
Oncology meets immunology: the cancer-immunity cycle. Immunity (2013) 5.60
Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol (2013) 5.43
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature (2014) 5.34
Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol (2013) 5.23
Differential DNA methylation in purified human blood cells: implications for cell lineage and studies on disease susceptibility. PLoS One (2012) 5.03
Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood (2009) 4.80
Tumor-associated macrophages: from mechanisms to therapy. Immunity (2014) 4.69
Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet (2013) 4.61
Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol (2011) 4.31
Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell (2015) 4.16
In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol (2009) 3.97
Expression of tumour-specific antigens underlies cancer immunoediting. Nature (2012) 3.89
Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns. Genes Cancer (2010) 3.78
Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt. Nat Protoc (2009) 3.77
Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell (2013) 3.75
NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics (2008) 3.59
Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity (2013) 3.50
Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature (2014) 3.42
T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol (2010) 3.39
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science (2016) 3.38
PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res (2007) 3.23
Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun (2013) 2.94
RNA-SeQC: RNA-seq metrics for quality control and process optimization. Bioinformatics (2012) 2.94
Systematic evaluation of spliced alignment programs for RNA-seq data. Nat Methods (2013) 2.92
The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res (2007) 2.34
Regulatory T cells in cancer immunotherapy. Curr Opin Immunol (2014) 2.32
Robust enumeration of cell subsets from tissue expression profiles. Nat Methods (2015) 2.30
GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics (2013) 2.29
Exploring TCGA Pan-Cancer data at the UCSC Cancer Genomics Browser. Sci Rep (2013) 2.19
VHL and HIF signalling in renal cell carcinogenesis. J Pathol (2010) 2.13
CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNFα. Cell Stem Cell (2012) 1.97
Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability. Immunity (2016) 1.96
Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med (2002) 1.95
SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution. PLoS Comput Biol (2014) 1.88
Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting. Clin Cancer Res (2015) 1.81
An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma. Cancer Cell (2016) 1.79
Identification of T cell-restricted genes, and signatures for different T cell responses, using a comprehensive collection of microarray datasets. J Immunol (2005) 1.73
RazerS 3: faster, fully sensitive read mapping. Bioinformatics (2012) 1.47
Mononuclear cell infiltration in clear-cell renal cell carcinoma independently predicts patient survival. Cancer (2006) 1.40
Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res (2004) 1.35
Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin Cancer Res (2004) 1.31
OptiType: precision HLA typing from next-generation sequencing data. Bioinformatics (2014) 1.26
MicroRNA-26a regulates pathological and physiological angiogenesis by targeting BMP/SMAD1 signaling. Circ Res (2013) 1.19
A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis. Cancer Cell (2013) 1.15
Emerging immunotherapies for renal cell carcinoma. Ann Oncol (2012) 1.11
Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas. J Pathol (2013) 1.09
Immunohistological detection of human cytotoxic/suppressor T cells using antibodies to a CD8 peptide sequence. J Clin Pathol (1992) 1.07
Gene and protein characteristics reflect functional diversity of CD56dim and CD56bright NK cells. J Leukoc Biol (2006) 1.06
DeconRNASeq: a statistical framework for deconvolution of heterogeneous tissue samples based on mRNA-Seq data. Bioinformatics (2013) 1.04
Profiling tissue-resident T cell repertoires by RNA sequencing. Genome Med (2015) 0.98
Endothelial cell-fatty acid binding protein 4 promotes angiogenesis: role of stem cell factor/c-kit pathway. Angiogenesis (2012) 0.97
Monoclonal antibody 123C3, identifying small cell carcinoma phenotype in lung tumours, recognizes mainly, but not exclusively, endocrine and neuron-supporting normal tissues. Int J Cancer Suppl (1988) 0.94
Spontaneous regression of renal cell carcinoma. Contemp Oncol (Pozn) (2013) 0.93
FOXP3 over-expression inhibits melanoma tumorigenesis via effects on proliferation and apoptosis. Oncotarget (2014) 0.93
c-Kit expression, angiogenesis, and grading in canine mast cell tumour: a unique model to study c-Kit driven human malignancies. Biomed Res Int (2014) 0.89
Effect of tumor-infiltrating lymphocyte subsets on prognosis and susceptibility to interferon therapy in patients with renal cell carcinoma. Urol Int (2002) 0.88
SnoN facilitates ALK1-Smad1/5 signaling during embryonic angiogenesis. J Cell Biol (2013) 0.81
Skewed T-helper (Th)1/2- and Th17/T regulatory‑cell balances in patients with renal cell carcinoma. Mol Med Rep (2014) 0.76
Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: A Randomized Clinical Trial. Eur Urol (2014) 3.27
An Arterial Based Complexity (ABC) Scoring System to Assess the Morbidity Profile of Partial Nephrectomy. Eur Urol (2015) 3.17
The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur Urol (2016) 1.79
The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. Eur Urol (2016) 1.65
Genomic Characterization of Upper Tract Urothelial Carcinoma. Eur Urol (2015) 1.51
A survey of DICER1 hotspot mutations in ovarian and testicular sex cord-stromal tumors. Mod Pathol (2015) 0.91
Preoperative predictive model of recovery of urinary continence after radical prostatectomy. BJU Int (2015) 0.80
Open mini-flank partial nephrectomy: an essential contemporary operation. Korean J Urol (2014) 0.79
Ontogeny of Tumor-associated Macrophages and Its Implication in Cancer Regulation. Trends Cancer (2016) 0.77
Low yield of surveillance imaging after surgery for T1 kidney cancer. World J Urol (2015) 0.75
Erratum to: Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biol (2017) 0.75
Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples. Eur Urol Focus (2016) 0.75
Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma. Eur Urol Focus (2017) 0.75
Genetic Basis of SMARCB1 Protein Loss in 22 Sinonasal Carcinomas. Hum Pathol (2020) 0.75
Dataset for reporting of carcinoma of the urethra (in urethrectomy specimens): recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology (2019) 0.75
Leiomyoma with bizarre nuclei: a morphological, immunohistochemical and molecular analysis of 31 cases. Mod Pathol (2017) 0.75
Prognostic Value of TERT Alterations and Mutational and Copy Number Alteration Burden in Urothelial Carcinoma. Eur Urol Focus (2017) 0.75
Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma. Eur Urol Focus (2016) 0.75
Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma. Eur Urol Focus (2017) 0.75
Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma. Eur Urol Focus (2016) 0.75
A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. Eur Urol (2017) 0.75
Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer. Prostate Cancer Prostatic Dis (2020) 0.75
A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response. Nat Commun (2020) 0.75
Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets. Eur Urol (2017) 0.75